AstraZeneca-Arbitrage Possibilities

May 13th, 2014 by hackel Leave a reply »

The clear rejection by the Board of AstraZeneca to Pfizer may not necessarily mean a permanent end to a deal. This reports reveals what the Board needs to hear and the possibility of such taking place.


This report available to consulting clients of CT Capital LLC. Contact or for information


Comments are closed.